Simurosertib is under clinical development by Millennium Pharmaceuticals and currently in Phase I for Uterine Cancer. According to GlobalData, Phase I drugs for Uterine Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Simurosertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TAK-931 is under development for the treatment of advanced non-hematologic solid tumors like ovarian cancer, metastatic colorectal cancer, uterine cancer, squamous esophageal cancer, rectal adenocarcinoma, metastatic pancreatic adenocarcinoma, squamous non-small cell lung cancer and squamous esophageal cancer. The drug candidate is administered through oral route as a capsule. It acts by targeting cell division cycle 7 (CDC7) protein kinase. The drug candidate is a selective Thieno [3,2-d] pyrimidinone with a quinuclidine moiety.
Millennium Pharmaceuticals overview
Millennium Pharmaceuticals (Takeda Oncology), a subsidiary of Takeda Pharmaceutical Co Ltd, is a biopharmaceutical company that offers cancer therapy for the treatment of patients with multiple myeloma and relapsed mantle cell lymphoma. Takeda Oncology is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Simurosertib’s drug-specific PTSR and LoA scores, buy the report here.